



DESCRIPTION	
Species Reactivity	Human
Specificity	Detects human TRAIL R3/TNFRSF10C in direct ELISAs and Western blots. In direct ELISAs, less than 5% cross-reactivity with recombinant human (rh) TRAIL R1, and rhTRAIL R2 is observed.
Source	Polyclonal Goat IgG
Purification	Antigen Affinity-purified
Immunogen	Mouse myeloma cell line NS0-derived recombinant human TRAIL R3/TNFRSF10C Ala26-Ala221 Accession # O14798
Endotoxin Level	<0.10 EU per 1 µg of the antibody by the LAL method.
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied as a 0.2 µm filtered solution in PBS.

APPLICATIONS		
Please Note: Optimal dilutions should be determined by each laboratory for each application. <i>General Protocols</i> are available in the <i>Technical Information</i> section on our website.		
	Recommended Concentration	Sample
Western Blot	0.5 µg/mL	See Below
Immunohistochemistry	5-15 µg/mL	Immersion fixed paraffin-embedded sections of human brain (occipital cortex) subjected to Antigen Retrieval Reagent-Basic (Catalog # CTS013)
Neutralization	Measured by its ability to neutralize TRAIL R3/TNFRSF10C-mediated inhibition of cytotoxicity in the L-929 mouse fibroblast cell line. The Neutralization Dose (ND ₅₀) is typically 0.015-0.045 µg/mL in the presence of 20 ng/mL Recombinant Human TRAIL R3/TNFRSF10C Fc Chimera, 12 ng/mL of Recombinant Human TRAIL, and 1 µg/mL actinomycin D.	

DATA	
<p>Western Blot</p>  <p>Detection of Human TRAIL R3/TNFRSF10C by Western Blot. Western blot shows lysates of L-929 mouse fibroblast cell line, THP-1 human acute monocytic leukemia cell line, and WS-1 human fetal skin fibroblast cell line. PVDF membrane was probed with 0.5 µg/mL of Goat Anti-Human TRAIL R3/TNFRSF10C Antigen Affinity-purified Polyclonal Antibody (Catalog # AF630) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF019). A specific band was detected for TRAIL R3/TNFRSF10C at approximately 27 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.</p>	<p>Neutralization</p>  <p>TRAIL R3/TNFRSF10C Inhibition of TRAIL/TNFSF10-induced Cytotoxicity and Neutralization by Human TRAIL R3/TNFRSF10C Antibody. In the presence of a cross-linking antibody, Mouse polyHistidine Monoclonal Antibody (5 µg/mL, Catalog # MAB050) and the metabolic inhibitor actinomycin D (1 µg/mL), Recombinant Human TRAIL R3/TNFRSF10C Fc Chimera (Catalog # 630-TR) inhibits Recombinant Human TRAIL/TNFSF10 (Catalog # 375-TL) induced cytotoxicity in the L-929 mouse fibroblast cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Under these conditions, inhibition of Recombinant Human TRAIL/TNFSF10 (12 ng/mL) activity elicited by Recombinant Human TRAIL R3/TNFRSF10C Fc Chimera (20 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human TRAIL R3/TNFRSF10C Antigen Affinity-purified Polyclonal Antibody (Catalog # AF630). The ND₅₀ is typically 0.015-0.045 µg/mL.</p>

PREPARATION AND STORAGE

Reconstitution	Reconstitute at 0.2 mg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none">● 12 months from date of receipt, -20 to -70 °C as supplied.● 1 month, 2 to 8 °C under sterile conditions after reconstitution.● 6 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

Human TRAIL R3, also called DcR1 (decoy receptor 1), LIT, and TRID, is a glycosyl-phosphatidylinositol-linked membrane protein which binds TRAIL (Apo2 Ligand) with high affinity. In the new TNF superfamily nomenclature, TRAIL R3 is referred to as TNFRSF10C. TRAIL R3 has the TRAIL-binding extracellular cysteine-rich domains but lacks the intracellular signalling domain. As a result, binding of TRAIL to TRAIL R3 does not transduce an apoptosis signal. Expression of TRAIL R3 has been shown to protect cells bearing TRAIL R1 and/or TRAIL R2 from TRAIL-induced apoptosis. A second TRAIL decoy receptor, which binds TRAIL with high-affinity but antagonizes TRAIL-induced apoptosis, named TRAIL R4, DcR2 or TRUNDD, has also been reported. The human soluble TRAIL R3/Fc chimera neutralizes the ability of TRAIL to induce apoptosis.

References:

1. Sheridan, J.P. *et al.* (1997) *Science* **277**:818.
2. Golstein, P. (1997) *Curr. Biol.* **7**:R750.